Contact Lenses for Visual Acuity

Overseen By Study Contact

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Johnson & Johnson Vision Care, Inc.

Must not be taking: Ocular medications

Disqualifiers: Pregnancy, Diabetes, Ocular allergies, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

Duration: 3 visits

36 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This will be a 3-visit, single-site, randomized, single-masked, bilateral wear, non-dispensing, crossover study which will evaluate visual performance with different magnitudes of scatter.

Who Is on the Research Team?

Johnson & Johnson Vision Care, Inc. Clinical Trial

Principal Investigator

Johnson & Johnson Vision Care, Inc.

Are You a Good Fit for This Trial?

Inclusion Criteria

4. Habitually wear soft contact lenses (either spherical or multifocal) in both eyes in a daily reusable or daily disposable wear modality (i.e., not extended wear modality). Habitual wearer is defined as a minimum of 6 hours per day, for a minimum of 2 days per week during the past 30 days.

5. Possess a wearable pair of spectacles that provide correction for distance vision.

I am between 18 and 69 years old.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants are evaluated for visual performance with different magnitudes of scatter over 3 visits

3 visits

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2-4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• ACUVUE® OASYS 1-Day Sphere
• ACUVUE® OASYS Multifocal

How Is the Trial Designed?

Group I: No filter/Filter 1/4mm/Filter 1/2mm/Filter 1mm/Filter 2mm Experimental Treatment 2 Interventions

Eligible subjects will be randomly assigned to the No filter/Filter 1/4mm/Filter 1/2mm/Filter 1mm/Filter 2mm sequence

Group II: Filter 2mm/No filter/Filter 1/4mm/Filter 1/2mm/Filter 1mm Experimental Treatment 2 Interventions

Eligible subjects will be randomly assigned to the Filter 2mm/No filter/Filter 1/4mm/Filter 1/2mm/Filter 1mm sequence

Group III: Filter 1mm/Filter 2mm/No filter/Filter 1/4mm/Filter 1/2mm Experimental Treatment 2 Interventions

Eligible subjects will be randomly assigned to the Filter 1mm/Filter 2mm/No filter/Filter 1/4mm/Filter 1/2mm sequence

Group IV: Filter 1/4mm/Filter 1/2mm/Filter 1mm/Filter 2mm/No filter Experimental Treatment 2 Interventions

Eligible subjects will be randomly assigned to the Filter 1/4mm/Filter 1/2mm/Filter 1mm/Filter 2mm/No filter sequence

Group V: Filter 1/2mm/Filter 1mm/Filter 2mm/No filter/Filter 1/4mm Experimental Treatment 2 Interventions

Eligible subjects will be randomly assigned to the Filter 1/2mm/Filter 1mm/Filter 2mm/No filter/Filter 1/4mm sequence

Who Is Running the Clinical Trial?

Johnson & Johnson Vision Care, Inc.

Lead Sponsor

Trials

224

Recruited

26,100+

Top Products

- ACUVUE® disposable contact lenses - TECNIS® intraocular lenses - LASIK vision correction systems

Joaquin Duato

Johnson & Johnson Vision Care, Inc.

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD

Johnson & Johnson Vision Care, Inc.

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University